Article
Case report: Complete response of an anaplastic thyroid carcinoma patient with NRAS Q61R/BRAF D594N mutations to the triplet of dabrafenib, trametinib and PD-1 antibody.
Frontiers in immunology - 1 Jan 2023
Gui Lin, Zhu Yiming, Li Xiaomo, He Xiaohui, Ma Tonghui, Cai Yi, Liu Shaoyan
Abstract excerpt
Anaplastic thyroid carcinoma, BRAF non-V600, NRAS, combination immunotherapy and targeted therapy, case report. Anaplastic thyroid carcinoma (ATC) is a rare type of thyroid cancer with a mortality rate near 100%. BRAF V600 and NRAS mutations are the most common drivers of ATC. While patients with BRAF V600-mutated ATC can be treated with BRAF-targeted therapy, there is no effective treatment for ATC driven by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.